Published in Cancer Res on August 31, 2012
NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol (2013) 1.46
Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecol Oncol (2014) 1.01
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. Cancer Res (2013) 0.89
Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21. Oncotarget (2014) 0.89
Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers. Adv Drug Deliv Rev (2014) 0.88
Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem (2013) 0.88
A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer. Cancer Res (2015) 0.86
Transcriptional regulation of chemokine expression in ovarian cancer. Biomolecules (2015) 0.77
Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin. J Interferon Cytokine Res (2014) 0.77
Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling. Oncotarget (2016) 0.77
IKKε and TBK1 expression in gastric cancer. Oncotarget (2017) 0.76
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol (2016) 0.75
Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment. Clin Cancer Res (2016) 0.75
BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1). Oncotarget (2017) 0.75
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov (2017) 0.75
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell (2007) 7.74
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 4.08
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell (2009) 2.00
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol (2007) 1.80
Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics (2010) 1.57
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res (2010) 1.48
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer (2010) 1.35
Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am J Pathol (2010) 1.31
Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol (2009) 1.20
Chemotherapy in epithelial ovarian cancer. Cancer Lett (2011) 1.18
Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol (2009) 1.16
Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis (2010) 1.14
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer (2001) 1.09
Identification of EPSTI1, a novel gene induced by epithelial-stromal interaction in human breast cancer. Genomics (2002) 1.08
Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. Cancer Sci (2009) 0.97
Ovarian cancer in the proteomics era. Int J Gynecol Cancer (2008) 0.86
Effect of intraperitoneal administration of granulocyte/macrophage-colony-stimulating factor in rats on omental milky-spot composition and tumoricidal activity in vivo and in vitro. Cancer Immunol Immunother (1996) 0.83
Is omentectomy mandatory in the operation for ovarian cancer? Preliminary results in a rat study. Eur J Obstet Gynecol Reprod Biol (2012) 0.82
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature (2006) 2.60
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med (2002) 2.58
A progeroid syndrome in mice is caused by defects in A-type lamins. Nature (2003) 2.57
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Dysfunctional connections between the nucleus and the actin and microtubule networks in laminopathic models. Biophys J (2008) 1.92
Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res (2004) 1.89
Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and MyoD pathways during muscle regeneration. Hum Mol Genet (2006) 1.85
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2010) 1.82
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer (2008) 1.62
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A (2007) 1.61
The lipid phosphatase LPP3 regulates extra-embryonic vasculogenesis and axis patterning. Development (2003) 1.57
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A (2006) 1.52
Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch (2006) 1.49
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res (2010) 1.48
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol (2010) 1.45
The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J (2010) 1.41
CD157 in ovarian carcinoma: how does it help us? J Natl Cancer Inst (2010) 1.38
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions. Diagn Cytopathol (2003) 1.36
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer (2010) 1.35
Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther (2006) 1.32
Proline oxidase functions as a mitochondrial tumor suppressor in human cancers. Cancer Res (2009) 1.31
Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res (2004) 1.28
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res (2005) 1.22
Laminin-induced signaling in tumor cells. Cancer Lett (2005) 1.21
miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med (2011) 1.21
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol (2006) 1.21
Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol (2010) 1.20
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood (2009) 1.18
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol (2005) 1.16
Adipose tissue: a vital in vivo role in mammary gland development but not differentiation. Dev Dyn (2002) 1.15
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol (2008) 1.11
Retracted Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling. J Clin Oncol (2005) 1.09
Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol (2009) 1.08
Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation. Genes Chromosomes Cancer (2013) 1.07
Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol (2010) 1.07
Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. J Oncol (2010) 1.07
Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One (2010) 1.06
Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res (2006) 1.06
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Why RECIST works and why it should stay--counterpoint. Cancer Res (2012) 1.05
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis (2010) 1.04
A model for obesity and gigantism due to disruption of the Ankrd26 gene. Proc Natl Acad Sci U S A (2007) 1.03
Do random estimations of vitamin D3 and parathyroid hormone reflect the 24-h profile in the critically ill? Intensive Care Med (2011) 1.02
A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. J Cancer (2012) 1.02
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol (2009) 1.00
Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer (2006) 0.99
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. Hum Pathol (2012) 0.99
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer (2014) 0.99
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer (2008) 0.98
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer (2007) 0.98
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A (2012) 0.96
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva. Genes Chromosomes Cancer (2013) 0.96
Genomic aberrations in borderline ovarian tumors. J Transl Med (2010) 0.95
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol (2009) 0.95
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer (2008) 0.95
The diagnostic role of claudins in serous effusions. Am J Clin Pathol (2007) 0.95
The lamin B receptor under transcriptional control of C/EBPepsilon is required for morphological but not functional maturation of neutrophils. Hum Mol Genet (2008) 0.94
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clin Cancer Res (2007) 0.94
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int J Cancer (2010) 0.93
Functions of the nuclear envelope and lamina in development and disease. Biochem Soc Trans (2008) 0.93
S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep (2012) 0.93
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol (2011) 0.92
DNA hypomethylation caused by Lsh deletion promotes erythroleukemia development. Epigenetics (2008) 0.92
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. Int J Surg Pathol (2002) 0.92
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch (2006) 0.92
Proteomics in clinical trials and practice: present uses and future promise. Mol Cell Proteomics (2006) 0.92
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer (2011) 0.91
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. Hum Pathol (2011) 0.91
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol (2004) 0.91
Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma. Int J Mol Sci (2011) 0.91
Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch (2014) 0.90
Large scale genomic instability as an additive prognostic marker in early prostate cancer. Cell Oncol (2009) 0.90
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol (2007) 0.90
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum Pathol (2013) 0.90
Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res (2008) 0.89
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer (2005) 0.89
Cystic change in metastatic lymph nodes: a common diagnostic pitfall in fine-needle aspiration cytology. Diagn Cytopathol (2002) 0.89
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol Oncol (2004) 0.89
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer (2005) 0.89
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol (2010) 0.88
Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma. PLoS One (2012) 0.88
Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin Cancer Res (2007) 0.87
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Hum Pathol (2009) 0.87
Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications. Virchows Arch (2009) 0.87
Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol (2009) 0.87
Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma. Mod Pathol (2006) 0.87
RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12). Genes Chromosomes Cancer (2013) 0.87
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. Hum Pathol (2011) 0.86
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters. Am J Clin Pathol (2009) 0.86
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol (2003) 0.86